Yes, I think so. Also heard Mr. Novik a while ago. Seems the comp believes so. Said they got orphan designation and therefore needs only one pivotal phase III for approval. They are going to start the phase III trial of hGH-CTP in adult early next year. Design is: 150 patients, 2 arms (vs placebo), 6 months treatment with 6-12 extension for safety, primary endpoint will be change in truncal fat, cost ~ $15M, NDA filing in 2015.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.